The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.
The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.
复制标题
microRNA-34a 在乳腺癌中的诊断作用：系统评价和荟萃分析
DOI：
10.18632/oncotarget.15520
复制
发表时间：
2017-04-04
期刊：
影响因子：
--
通讯作者：
Fu J
中科院分区：
文献类型：
--
作者：
Imani S;Zhang X;Hosseinifard H;Fu S;Fu J
背景MicroRNA-34 a（miR-34 a）是乳腺癌（BC）肿瘤抑制的主要调节因子。本系统评价旨在分析miR-34 a作为生物标志物检测BC的诊断准确性。结果共纳入1858例BC病例和494例对照，来自9篇文献报道的13项合格研究。总的合并敏感性、特异性、阴性似然比（NLR）、阳性似然比（PLR）和诊断优势比（DOR）为85.50%（95% CI：83.80-87.00%）、70.00%（95% CI：65.80-74.10%）、0.29（95% CI：0.19-0.43）、2.58（95% CI：1.91-3.43）和9.39（95% CI：5.47-16.12）。类似地，概括受试者工作特征（SROC）的总曲线下面积（AUC）为0.80，表明miR-34 a作为生物标志物的高度保守性。此外，亚组分析表明，使用miR-34 a作为生物标志物在基于组织的侵袭性BC样本中更准确。我们还表明，miR-34 a是诊断高加索人BC的一种有效生物标志物。材料和方法对符合条件的发表文献进行系统检索，这些文献涉及BC病例和非癌对照中的miR-34 a表达水平。使用合并的灵敏度和特异性、DOR和SROC的AUC评估miR-34 a对BC的诊断能力。PLR和NLR在临床水平上可用于评估miR-34 a诊断的准确性。通过QUADAS-2评估纳入研究的质量。结论miR-34 a是一种有希望的诊断乳腺癌的非侵袭性生物标志物。应实施设计良好的队列研究，以保证miR-34 a在临床上的诊断价值。
Background MicroRNA-34a (miR-34a) is a master regulator of tumor suppression in breast cancer (BC). This systematic review aims to analyze the diagnostic accuracy of miR-34a in the detection of BC as a biomarker. Results A total of 1858 BC cases and 494 controls from thirteen eligible studies reported in 9 publications were included. The overall pooled sensitivity, specificity, negative likelihood ratio (NLR), positive likelihood ratio (PLR), and diagnostic odds ratio (DOR) were 85.50% (95% CI: 83.80-87.00%), 70.00% (95% CI: 65.80–74.10%), 0.29 (95% CI: 0.19–0.43), 2.58 (95% CI: 1.91–3.43), and 9.39 (95% CI: 5.47–16.12), respectively. Similarly, the overall area under the curve (AUC) of the summary receiver operating characteristic (SROC) was 0.80, indicating the high conservation of miR-34a as a biomarker. Furthermore, subgroup analysis suggested that the use of miR-34a as a biomarker is more accurate in tissue-based sample of invasive BC. We also indicated that miR-34a is a capable biomarker in diagnosing BC in people of Caucasian descent. Materials and Methods A systematic search was conducted for eligible publications that address miR-34a expression level in BC cases and noncancerous controls. Diagnostic capacity of miR-34a for BC was assessed using pooled sensitivity and specificity, DOR, and AUC of SROC. PLR and NLR were verified to estimate the miR-34a diagnostic accuracy in clinical level. The quality of the included studies was assessed by QUADAS-2. Conclusions These findings suggest miR-34a is a promising non-invasive biomarker in diagnosing BC. Well-designed cohort studies should be implemented to warrant the diagnostic value of miR-34a in clinical purposes.